阿尔茨海默病的转录风险得分:从病理学到认知
Jung-Min Pyun1, Young Ho Park2, Jiebiao Wang3
1Department of Neurology, Soonchunhyang University Seoul Hospital, Soonchunhyang University College of Medicine, Yongsan-gu, Seoul, Republic of Korea.
概括
基于大脑的转录风险评分 (TRS) 显示了与阿尔茨海默病 (AD) 诊断,病理学和认知衰退的显著关联. 这些评分提高了现有的AD多基因风险评分 (PRS) 的分类性能.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 遗传学是一种遗传学.
- 生物标志物 生物标志物
背景情况:
- 之前开发的基于血液的转录风险评分 (TRS) 显示了与阿尔茨海默病 (AD) 诊断和神经成像生物标志物的关联.
- 阿尔茨海默病 (AD) 构成了全球重大健康挑战,需要改进诊断和预后工具.
研究的目的:
- 为阿尔茨海默病 (AD) 开发和验证基于大脑的转录风险得分 (TRS).
- 评估基于大脑的TRS与AD诊断,神经病理学 (粉样性病变,性病变) 和认知功能之间的关联.
- 评估基于大脑的TRS在改善AD多基风险评分 (PRS) 的分类性能方面的贡献.
主要方法:
- 综合AD全基因组关联研究摘要和表达量化特征位置数据,使用门德尔随机化来识别目标基因.
- 使用两个独立队列 (N=878) 的脑转录组数据计算TRS.
- 进行了TRS与阿尔茨海默氏症诊断,粉样性病,性病和认知的关联分析,将其性能与PRS进行了比较.
主要成果:
- 较高的基于大脑的TRS值与阿尔茨海默病诊断,粉样蛋白病,形蛋白病和更差的认知表现有显著的关联.
- 这些关联在一个独立的队列中被复制,证实了研究结果的稳定性.
- 将TRS纳入PRS的AD分类性能提高了高达16%,实现曲线下的面积为0.850.
结论:
- 基于大脑的TRS作为阿尔茨海默病 (AD) 的潜在生物标志物.
- 基于大脑的TRS集成增强了现有的多基因风险评分 (PRS) 的预测和分类能力.
- 这些发现支持基于大脑的转录分析对理解和诊断AD的有用性.
关键词:
阿尔茨海默病的疾病阿尔茨海默病的疾病.氨基胺病变 - 氨基胺病变认知 认知 认知认知能力下降 认知能力下降多基因风险评分多基因风险评分.病症是一种病症.转录风险分数的成绩.转录组 (transcriptome) 是一个转录组.更多相关视频
04:22Author Spotlight: Exploring Sex-Specific Glial Signatures and Therapeutic Leads for Alzheimer's Disease
Published on: May 20, 2024
895
09:38Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
15.0K
相关概念视频
01:26Alzheimer's Disease: Overview
521
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
521
01:22Alzheimer's Disease: Treatment
215
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
215
02:28Leaky Scanning
5.2K
During most eukaryotic translation processes, the small 40S ribosome subunit scans an mRNA from its 5' end until it encounters the first start AUG codon. The large 60S ribosomal subunit then joins the smaller one to initiate protein synthesis. The location of the translation initiation is largely determined by the nucleotides near the start codon as there may be multiple translation initiation sites present on the mRNA. Marilyn Kozak discovered that the sequence RCCAUGG (where R...
5.2K